Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy

Satoshi Ono, Mitsuhiro Fujishiro, Kousuke Hirano, Keiko Niimi, Osamu Goto, Shinya Kodashima, Nobutake Yamamichi, Kazuhiko Koike

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: The guideline on the management of anticoagulants and antiplatelet agents for endoscopic procedures was established by the Japan Gastroenterological Endoscopy Society in 2005. However, the degree to which this guideline has reached prescribing doctors in other fields has not, so far, been evaluated. Method: Medical records of all patients who underwent scheduled endoscopy from January 2008 to December 2008 in the Department of Gastroenterology at the University of Tokyo were investigated retrospectively. Results: Among 8921 patients underwent scheduled endoscopy, 1383 patients (15.5%) were receiving anticoagulants or antiplatelet agents. 324 patients (23.4%) were receiving warfarin as an anticoagulant. The most common antiplatelet agent was aspirin in 884 patients (63.9%), followed by ticlopidine in 150 patients (10.8%). Most patients taking warfarin alone (51.6%) or a combination of aspirin and ticlopidine (68.4%) underwent endoscopy without cessation. In contrast, most patients taking aspirin alone (46.0%) or ticlopidine alone (56.3%) underwent endoscopy after a cessation period of 6-7 days, indicating the low permeation of the cessation policy recommended in the guideline. Among 556 patients underwent endoscopy without a cessation period, 41 patients (7.4%) underwent invasive procedures including endoscopic mucosal resection. No bleeding complications were observed in patients who underwent invasive procedures without a cessation period. Conclusion: We revealed the low permeation of the guideline to prescribing doctors. Cessation before endoscopy to avoid bleeding complications can be dispensable.

Original languageEnglish
Pages (from-to)1185-1189
Number of pages5
JournalJournal of Gastroenterology
Volume44
Issue number12
DOIs
Publication statusPublished - 2009 Dec
Externally publishedYes

Fingerprint

Platelet Aggregation Inhibitors
Anticoagulants
Endoscopy
Ticlopidine
Guidelines
Aspirin
Warfarin
Hemorrhage
Tokyo
Gastroenterology
Medical Records

Keywords

  • Anticoagulant
  • Antiplatelet agent
  • Cessation
  • Complication
  • Endoscopy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ono, S., Fujishiro, M., Hirano, K., Niimi, K., Goto, O., Kodashima, S., ... Koike, K. (2009). Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. Journal of Gastroenterology, 44(12), 1185-1189. https://doi.org/10.1007/s00535-009-0127-6

Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. / Ono, Satoshi; Fujishiro, Mitsuhiro; Hirano, Kousuke; Niimi, Keiko; Goto, Osamu; Kodashima, Shinya; Yamamichi, Nobutake; Koike, Kazuhiko.

In: Journal of Gastroenterology, Vol. 44, No. 12, 12.2009, p. 1185-1189.

Research output: Contribution to journalArticle

Ono, S, Fujishiro, M, Hirano, K, Niimi, K, Goto, O, Kodashima, S, Yamamichi, N & Koike, K 2009, 'Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy', Journal of Gastroenterology, vol. 44, no. 12, pp. 1185-1189. https://doi.org/10.1007/s00535-009-0127-6
Ono, Satoshi ; Fujishiro, Mitsuhiro ; Hirano, Kousuke ; Niimi, Keiko ; Goto, Osamu ; Kodashima, Shinya ; Yamamichi, Nobutake ; Koike, Kazuhiko. / Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. In: Journal of Gastroenterology. 2009 ; Vol. 44, No. 12. pp. 1185-1189.
@article{ccb077a53dd44b8a9f278788a13e94aa,
title = "Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy",
abstract = "Background: The guideline on the management of anticoagulants and antiplatelet agents for endoscopic procedures was established by the Japan Gastroenterological Endoscopy Society in 2005. However, the degree to which this guideline has reached prescribing doctors in other fields has not, so far, been evaluated. Method: Medical records of all patients who underwent scheduled endoscopy from January 2008 to December 2008 in the Department of Gastroenterology at the University of Tokyo were investigated retrospectively. Results: Among 8921 patients underwent scheduled endoscopy, 1383 patients (15.5{\%}) were receiving anticoagulants or antiplatelet agents. 324 patients (23.4{\%}) were receiving warfarin as an anticoagulant. The most common antiplatelet agent was aspirin in 884 patients (63.9{\%}), followed by ticlopidine in 150 patients (10.8{\%}). Most patients taking warfarin alone (51.6{\%}) or a combination of aspirin and ticlopidine (68.4{\%}) underwent endoscopy without cessation. In contrast, most patients taking aspirin alone (46.0{\%}) or ticlopidine alone (56.3{\%}) underwent endoscopy after a cessation period of 6-7 days, indicating the low permeation of the cessation policy recommended in the guideline. Among 556 patients underwent endoscopy without a cessation period, 41 patients (7.4{\%}) underwent invasive procedures including endoscopic mucosal resection. No bleeding complications were observed in patients who underwent invasive procedures without a cessation period. Conclusion: We revealed the low permeation of the guideline to prescribing doctors. Cessation before endoscopy to avoid bleeding complications can be dispensable.",
keywords = "Anticoagulant, Antiplatelet agent, Cessation, Complication, Endoscopy",
author = "Satoshi Ono and Mitsuhiro Fujishiro and Kousuke Hirano and Keiko Niimi and Osamu Goto and Shinya Kodashima and Nobutake Yamamichi and Kazuhiko Koike",
year = "2009",
month = "12",
doi = "10.1007/s00535-009-0127-6",
language = "English",
volume = "44",
pages = "1185--1189",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "12",

}

TY - JOUR

T1 - Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy

AU - Ono, Satoshi

AU - Fujishiro, Mitsuhiro

AU - Hirano, Kousuke

AU - Niimi, Keiko

AU - Goto, Osamu

AU - Kodashima, Shinya

AU - Yamamichi, Nobutake

AU - Koike, Kazuhiko

PY - 2009/12

Y1 - 2009/12

N2 - Background: The guideline on the management of anticoagulants and antiplatelet agents for endoscopic procedures was established by the Japan Gastroenterological Endoscopy Society in 2005. However, the degree to which this guideline has reached prescribing doctors in other fields has not, so far, been evaluated. Method: Medical records of all patients who underwent scheduled endoscopy from January 2008 to December 2008 in the Department of Gastroenterology at the University of Tokyo were investigated retrospectively. Results: Among 8921 patients underwent scheduled endoscopy, 1383 patients (15.5%) were receiving anticoagulants or antiplatelet agents. 324 patients (23.4%) were receiving warfarin as an anticoagulant. The most common antiplatelet agent was aspirin in 884 patients (63.9%), followed by ticlopidine in 150 patients (10.8%). Most patients taking warfarin alone (51.6%) or a combination of aspirin and ticlopidine (68.4%) underwent endoscopy without cessation. In contrast, most patients taking aspirin alone (46.0%) or ticlopidine alone (56.3%) underwent endoscopy after a cessation period of 6-7 days, indicating the low permeation of the cessation policy recommended in the guideline. Among 556 patients underwent endoscopy without a cessation period, 41 patients (7.4%) underwent invasive procedures including endoscopic mucosal resection. No bleeding complications were observed in patients who underwent invasive procedures without a cessation period. Conclusion: We revealed the low permeation of the guideline to prescribing doctors. Cessation before endoscopy to avoid bleeding complications can be dispensable.

AB - Background: The guideline on the management of anticoagulants and antiplatelet agents for endoscopic procedures was established by the Japan Gastroenterological Endoscopy Society in 2005. However, the degree to which this guideline has reached prescribing doctors in other fields has not, so far, been evaluated. Method: Medical records of all patients who underwent scheduled endoscopy from January 2008 to December 2008 in the Department of Gastroenterology at the University of Tokyo were investigated retrospectively. Results: Among 8921 patients underwent scheduled endoscopy, 1383 patients (15.5%) were receiving anticoagulants or antiplatelet agents. 324 patients (23.4%) were receiving warfarin as an anticoagulant. The most common antiplatelet agent was aspirin in 884 patients (63.9%), followed by ticlopidine in 150 patients (10.8%). Most patients taking warfarin alone (51.6%) or a combination of aspirin and ticlopidine (68.4%) underwent endoscopy without cessation. In contrast, most patients taking aspirin alone (46.0%) or ticlopidine alone (56.3%) underwent endoscopy after a cessation period of 6-7 days, indicating the low permeation of the cessation policy recommended in the guideline. Among 556 patients underwent endoscopy without a cessation period, 41 patients (7.4%) underwent invasive procedures including endoscopic mucosal resection. No bleeding complications were observed in patients who underwent invasive procedures without a cessation period. Conclusion: We revealed the low permeation of the guideline to prescribing doctors. Cessation before endoscopy to avoid bleeding complications can be dispensable.

KW - Anticoagulant

KW - Antiplatelet agent

KW - Cessation

KW - Complication

KW - Endoscopy

UR - http://www.scopus.com/inward/record.url?scp=73449130126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449130126&partnerID=8YFLogxK

U2 - 10.1007/s00535-009-0127-6

DO - 10.1007/s00535-009-0127-6

M3 - Article

VL - 44

SP - 1185

EP - 1189

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 12

ER -